Arixtra (fondaparinux sodium) is an oligosaccharide pharmaceutical. Fondaparinux sodium was first approved as Arixtra on 2001-12-07. It is used to treat pulmonary embolism and venous thrombosis in the USA. It has been approved in Europe to treat myocardial infarction, pulmonary embolism, unstable angina, and venous thrombosis. The pharmaceutical is active against antithrombin-III.
|Common Name||Fondaparinux sodium|
|Indication||myocardial infarction, pulmonary embolism, unstable angina, venous thrombosis|
|Drug Class||Antithrombotyic indirect selective synthetic factor Xa inhibitors|